bioAffinity Technologies, Inc. (NASDAQ: BIAF)

BioAffinity Technologies, Inc., a prominent player in the biotechnology industry, is known for its development of non-invasive diagnostic tests to detect early-stage lung cancer and other lung diseases. The company's primary product, CyPath Lung, is a test that utilizes flow cytometry technology to analyze cell populations in a person's sputum to identify characteristics indicative of lung cancer.

BioAffinity's business model revolves around the creation and commercialization of its proprietary diagnostic tests, including CyPath Lung. These tests are designed to complement other diagnostic tools, such as computed tomography (CT) scans, to provide a more comprehensive understanding of a patient's lung health. The company's tests are user-friendly and can be performed in various settings, including physician offices, hospitals, and clinics.

CyPath Lung is a non-invasive diagnostic test that uses flow cytometry technology to analyze cell populations in a person's sputum. The test is designed to be used in a variety of settings, such as physician offices, hospitals, and clinics. CyPath Lung employs a proprietary algorithm to analyze the data collected from the flow cytometry test and generate a report that indicates the likelihood of lung cancer.

BioAffinity Technologies, Inc. holds a strong position within the industry, boasting a unique and proprietary diagnostic test that has demonstrated high accuracy and sensitivity in clinical trials. The company's tests are designed to be user-friendly and can be performed in various settings, including physician offices, hospitals, and clinics.

The company's competitive advantages include its proprietary diagnostic test, user-friendly design, and ability to detect lung cancer at an early stage. CyPath Lung is also cost-effective, with a Medicare reimbursement code billable to both government and private insurance carriers.

BioAffinity Technologies, Inc. caters to a diverse range of customers, including healthcare providers such as physicians, hospitals, and clinics. These customers utilize the company's diagnostic tests to diagnose and treat patients with lung cancer and other lung diseases.

In addition to its diagnostic tests, BioAffinity Technologies, Inc. is engaged in research and development activities aimed at expanding its platform technology to detect and monitor other lung diseases, such as chronic obstructive pulmonary disease (COPD) and asthma. The company is also conducting research on the use of its flow cytometry platform as a companion test to bronchoscopy.

Furthermore, the company's subsidiary, OncoSelect Therapeutics, LLC, is a preclinical-stage biopharmaceutical discovery company that focuses on developing therapeutics that deliver cytotoxic effects on a broad selection of human cancers while having little or no effect on normal cells.